Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV

Tess E. Peterson1*, Christian Landon2, Sabina A. Haberlen2, Fiona Bhondoekhan3, Michael W. Plankey4, Frank J. Palella5, Damani A. Piggott2,6, Joseph B. Margolick7, Todd T. Brown8, Wendy S. Post1,2† and Katherine C. Wu1†

Abstract

Background: Infection with human immunodeficiency virus (HIV) is associated with higher risk for myocardial disease despite modern combination antiretroviral therapy (cART). Factors contributing to this excess risk, however, remain poorly characterized. We aimed to assess cross-sectional relationships between elevations of left atrial volume index (LAVI) and myocardial extracellular volume (ECV) fraction that have been reported in persons living with HIV and levels of circulating biomarkers of inflammation, fibrosis, and myocyte stretch among persons living with and without HIV (PLWH, PLWOH).

Methods: Participants from three cohorts of PLWH and PLWOH underwent cardiovascular magnetic resonance imaging for measurement of LAVI and ECV. Levels of circulating proteins (IL-6, sCD14, galectin-3, NT-proBNP, GDF-15, TIMP-2, MMP-2, and hsTnI) were measured using immunoassays. Associations were assessed using logistic and linear regression, adjusting for demographics, substance use, and clinical characteristics.

Results: Among 381 participants with and without HIV, median age (IQR) was 55.1 (51.2, 58.4) years, 28% were female, 69% were Black, and 46% were current smokers. Sixty-two percent were PLWH (n = 235), of whom 88% were receiving cART and 72% were virally suppressed. PLWH had higher levels of sCD14 (p < 0.001), GDF-15 (p < 0.001), and NT-proBNP (p = 0.03) compared to PLWOH, while levels of other biomarkers did not differ by HIV serostatus, including IL-6 (p = 0.84). Among PLWH, higher sCD14, GDF-15, and NT-proBNP were also associated with lower CD4+ cell count, and higher NT-proBNP was associated with detectable HIV viral load. NT-proBNP was associated with elevated LAVI (OR: 1.79 [95% CI: 1.31, 2.44]; p < 0.001) with no evidence of effect measure modification by HIV serostatus. Other associations between HIV-associated biomarkers and LAVI or ECV were small or imprecise.

Conclusions: Our findings suggest that elevated levels of sCD14, GDF-15, and NT-proBNP among PLWH compared to PLWOH observed in the current cART era may only minimally reflect HIV-associated elevations in LAVI and ECV.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Combination antiretroviral therapy (cART) use among persons living with HIV (PLWH) has resulted in longer life expectancy and a shift in causes of morbidity and mortality from acquired immunodeficiency syndrome (AIDS)-defining conditions to chronic aging-related non-communicable diseases, such as cardiovascular disease (CVD) [1, 2]. Extensive evidence suggests that HIV infection in the current cART era is an independent risk factor for myocardial disease [3], including incident heart failure (HF) with both reduced (HFrEF) and preserved (HFpEF) ejection fraction [4–6] and sudden cardiac death [7, 8]. Factors contributing to this excess risk, however, remain poorly characterized.

Advanced HIV disease is associated with systolic dysfunction and dilated cardiomyopathy, but with the advent of effective cART came a transition from this phenotype to one characterized more by subclinical differences in cardiac structure and diastolic abnormalities which may ultimately contribute to higher risk of incident clinical HFpEF observed in the current treatment era [9, 10]. Among a contemporary population of cART-treated PLWH compared to persons living without HIV (PLWOH) in the same setting, we recently reported a higher left atrial volume index (LAVI) and myocardial extracellular volume (ECV) fraction—a measure of fibrosis, edema, or inflammation—using cardiac magnetic resonance (CMR) imaging [11], both of which may presage diastolic dysfunction and HFpEF. No other cardiac structural or functional characteristics differed significantly by HIV serostatus within that study population, and similar associations between HIV serostatus and both measures of myocardial fibrosis and diastolic abnormalities have been described in the United States, Europe, and Africa [12–18].

Contemporary data are needed to understand the pathogenesis of HIV-associated myocardial injury and remodeling. Several biomarkers have been studied for associations with cardiac structure and function among the general population, including those of inflammation, cardiac stress and injury, and extracellular matrix remodeling and fibrosis. However, these relationships have been understudied in the context of HIV infection, where they may differ due to immune dysregulation and chronically elevated systemic inflammation that persists even in the context of cART.

Inflammation is a hallmark of chronic HIV infection and is intimately involved in the pathology of tissue remodeling and fibrosis. When inflammatory responses to tissue insult are imbalanced, further tissue damage can occur via prolonged insult by the original injurious stimuli or persistent activation of inflammatory pathways [19]. Epidemiologic evidence also suggests higher circulating levels of inflammation and immune activation markers are associated with fibrosis across organ systems, including within the myocardium [16, 20, 21]. However, in the context of cART-treated HIV infection, the characterization of inflammatory markers that may contribute to myocardial injury and remodeling remains limited.

The objective of this study was to evaluate the cross-sectional relationships of biomarkers of inflammation, ventricular and cellular stress, tissue remodeling, and tissue injury with previously identified HIV-associated subclinical alterations in cardiac structure. We studied PLWH and PLWOH who were enrolled in one of three established cohort studies—the Multicenter AIDS Cohort Study (MACS), the Women’s Interagency HIV Study (WIHS), and the AIDS Linked to the Intravenous Experience (ALIVE) study—and we focused our analyses to biomarkers and the CMR structural metrics of LAVI and ECV, which were associated with HIV serostatus within this study population.

Methods

Study population

Active participants of MACS, WIHS, and ALIVE—each described in detail previously—were recruited and consented into the current study for CMR imaging under identical, standardized protocols from 2015 to 2018 [11]. Briefly, the MACS is a prospective cohort study of men who have sex with men living with and without HIV infection across four cities in the United States; the WIHS is a prospective cohort of women living with and without HIV infection across four cities in the United States; the WIHS is a prospective cohort of women living with and without HIV across ten US cities; and the ALIVE study is a community-based prospective cohort of persons with a history of injection drug use enrolled in Baltimore, MD. By nature of the parent cohort designs, sex at birth and substance use differed across cohorts—i.e., MACS participants were 100% male, WIHS participants were 100% female, and ALIVE participants had higher reported usage of opioids and stimulants. As previously

Future studies of excess risk of myocardial disease among contemporary cohorts of PLWH should investigate mechanisms other than those connoted by the studied biomarkers.

Keywords: Human immunodeficiency virus, Inflammation, Myocardial disease, Extracellular volume fraction, Left atrial volume, Fibrosis
reported, there were differences in other major factors across cohorts, such as race/ethnicity, with 47%, 5%, and 3% self-reported white participants in MACS, WIHS, and ALIVE, respectively [11]. Distribution of age, HIV seropositivity, and HIV-related factors such as cART use were similar across parent cohorts. Distributions of most important characteristics were similar between PWOH and PLWH—including age, sex, race/ethnicity, and traditional cardiovascular risk factors [11].

Participants of the current study were aged 40–70 years and actively enrolled in MACS, WIHS, or ALIVE at Chicago, Baltimore, or Washington, DC study sites. Exclusion criteria were any contraindications to CMR or contrast administration, including estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m², weight > 350 pounds, known claustrophobia, or known gadolinium contrast allergy.

Clinical data
Under protocols of each of the included parent cohorts, participants underwent structured semi-annual study visits, which included standardized interviews, physical examinations, and plasma collection and storage. Data collected include demographics, education, smoking status, systolic and diastolic blood pressures, body mass index (BMI), fasting glucose; total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels; serum creatinine, eGFR, hematocrit, and hepatitis C viral (HCV) infection status. Substance use variables were derived from data collected over the 5 years preceding CMR; any reported substance use during that time period is reported as use, and pack-years were calculated over this 5 year time period, not lifetime cumulative. In PLWH, measures of HIV disease activity included plasma HIV RNA concentrations (quantified down to 50 copies/mL, Roche ultrasensitive assay), current and nadir CD4+T cell counts/µL, history of AIDS-defining malignancy or opportunistic infection, and use of cART.

Participants enrolled in the current study underwent a single visit between March 2015 and February 2018 where CMR was performed and a structured interview was administered, collecting further data on prescribed medications, history of cardiovascular disease, and substance use—including alcohol, marijuana, opiates, stimulants, prescribed or recreational use of erectile dysfunction agents, and prescribed or recreational use of nitrates.

Cardiac magnetic resonance imaging
CMR was performed at Johns Hopkins Hospital (Baltimore, MD, USA) or Northwestern Memorial Hospital (Chicago, IL, USA) on 1.5T Siemens Avanto or Aera scanners (Erlangen, Germany) using a standardized protocol, described in detail previously and identical across these two sites [11]. Briefly, short- and long-axis cine images (30 phases/cardiac cycle) were acquired using a steady-state free precession sequence; two-dimensional late gadolinium enhancement short- and long-axis images were acquired using an inversion-recovery fast gradient-echo sequence 15 min post-intravenous administration of 0.2 mmol/kg of gadobutrol contrast (Gadavist®, Bayer, Montville, NJ, USA); and T1 mapping was ascertained using a modified Look-Locker inversion (MOLLI) recovery sequence both before and after contrast administration. All CMR analyses were performed blinded to HIV serostatus and other participant characteristics using Segment v2.0 (http://segment.heidelberg.se), Multimodality Tissue Tracking software (MTT; version 6.0, Toshiba, Japan), and MRmap version 1.2 (Charite University Medicine, Berlin, Germany).

LAVI and ECV fraction were selected as outcomes for the current analysis because they have been previously shown to differ by HIV serostatus in this study population [11]. Maximum LA volume was measured using the LA volume curve generated by the Simpson’s method from the four-chamber and two-chamber views and indexed by body surface area [22, 23]. Tracing of the LA borders excluded pulmonary veins and the left atrial appendage [22]. ECV fraction (%) was calculated as $ECV = 100 \times \frac{\text{partition coefficient}}{[1 - \text{hematocrit}]}$, where the partition coefficient was derived from the slope of the linear relationship of $1/T1_{\text{myocardium}}$ versus $1/T1_{\text{blood pre- and post-contrast}}$ [24].

Protein biomarkers
Blood was drawn from participants concurrent with CMR, and samples were processed for serum and plasma on the same day using standard protocols and stored at −80 °C until assays were performed. Biomarkers of inflammation (interleukin-6 [IL-6], soluble cluster of differentiation 14 [sCD14], galectin-3), ventricular and cellular stress (N-terminal prohormone of brain natriuretic peptide [NT-proBNP], growth differentiation factor-15 [GDF-15]), tissue remodeling (tissue inhibitor of metalloproteinase-2 [TIMP-2], matrix metalloproteinase-2 [MMP-2]) and tissue injury (high-sensitivity troponin I [hsTnI]) were measured in serum and plasma at central laboratories. Serum levels of IL-6 were measured by electrochemiluminescence (Meso Scale Discovery V-PLEX), and the following markers were measured by enzyme-linked immunosorbent assay: sCD14 (R&D Systems Quantikine), GDF-15 (R&D Systems Quantikine), TIMP-2 (R&D Systems Quantikine), and plasma HIV RNA concentrations.
Quantikine), MMP-2 (R&D Systems Quantikine), and NT-proBNP (Abbott Architect i2000sR) in serum, and galectin-3 (Abbott Architect i2000sR) and hsTnI (Abbott Architect i2000sR) in plasma.

Statistics

Biomarkers were winsorized to their 97th percentiles to limit the effect of outliers in modeling procedures and standardized for interpretability. Cardiac phenotypes of interest were dichotomized at normative thresholds as previously described [11]. Specifically, elevated left atrial volume was defined as ≥ 40 mL/m² following indexation by body surface area [25] and elevated ECV fraction was defined as ≥ 30% among women and ≥ 28% among men [26].

Participant characteristics, CMR imaging parameters (continuous and dichotomized LAVI and ECV fraction), and laboratory measures were summarized by median (interquartile range [IQR]) or proportion (count). The distributions of participant characteristics, including circulating biomarker levels and CMR parameters, were compared by HIV serostatus using the Wilcoxon rank-sum test for continuous variables and Pearson’s χ² test for categorical variables. In order to minimize multiple testing, only biomarkers that were associated with HIV serostatus were evaluated in subsequent analyses.

Among PLWH, analyses were performed using multivariable linear regression to estimate the associations between measures of HIV disease severity and biomarkers that differed by HIV serostatus (identified in the previous analytic step), adjusting for age, sex, race/ethnicity, education, pack-years of smoking over the 5 years preceding CMR, and hazardous alcohol use defined by an Alcohol Use Disorders Identification Test (AUDIT) score > 8 at the time of CMR. For these analyses, biomarker responses were modeled on the natural log scale. Exponentiated β coefficients are therefore the ratios of the geometric mean biomarker concentrations among those exposed versus unexposed to the HIV clinical factor.

The cross-sectional associations between HIV-associated biomarkers (identified in the previous analytic step) and HIV-associated cardiac phenotypes (high LAVI and high ECV fraction) were estimated per standard deviation increment in biomarker concentration using multivariable logistic regression. These regression models were adjusted for HIV serostatus, age, sex, race/ethnicity, education level, and traditional cardiovascular risk factors—specifically history of cardiovascular disease, average continuous systolic blood pressure measured over 5 years preceding CMR, antihypertensive medication, dyslipidemia (use of lipid-lowering medication, fasting total cholesterol level ≥ 200 mg/dL, LDL-cholesterol level ≥ 130 mg/dL, HDL-cholesterol level < 40 mg/dL, or serum triglyceride level ≥ 150 mg/dL), diabetes (use of hypoglycemic medication or fasting serum glucose levels ≥ 126 mg/dL at the cohort study visit closest to the time of the CMR study; hemoglobin A1C level < 6.5% was used to exclude diabetes if a participant was not using hypoglycemic medication and fasting glucose levels were unavailable), pack-years of smoking over 5 years preceding CMR, and hazardous alcohol use at the time of CMR. We selected this model based on hypothesized confounders and did not adjust for parent cohort due to collinearity with sex, i.e., WIHS enrolled only women and MACS enrolled only men.

To assess heterogeneity of the associations between biomarkers and outcomes by HIV serostatus, we stratified analyses by HIV serostatus and tested a multiplicative interaction term for each biomarker (HIV × biomarker) in separate regression models. The stratified models included the same covariates as in the unstratified analyses, with the exception of cardiovascular disease history and hypertension medication due to small cell counts. We also assessed whether inclusion of biomarkers attenuated the association between HIV serostatus and either high ECV or high LAVI by comparing HIV effect estimates from multivariable models with and without individual outcome-associated biomarkers included as covariates. Finally, post-hoc sensitivity analyses were performed to evaluate the impact of HCV infection and additional recreational drug use covariates—specifically marijuana, opioid, stimulant, erectile dysfunction drug, and nitrate use. All analyses were conducted using Stata 16.1 and SAS 9.4 with a type I error rate of 0.05.

Results

A total of 468 persons were initially enrolled across the three cohorts, of whom 381 had complete covariate data and either LAVI (n = 380) or ECV fraction (n = 319) acquired on CMR (Additional file 1: Figure S1). Demographic and clinical characteristics are presented in Table 1. Overall median age (IQR) was 55.1 (51.2, 58.4) years, 28% were female, 69% were Black, and 46% were current smokers. Sixty-two percent were PLWH, 88% of whom were receiving cART, and 72% of whom were virally suppressed. On average, PLWH had significantly higher levels of circulating sCD14 (p = < 0.001), GDF-15 (p = < 0.001), and NT-proBNP (p = 0.03) compared to PLWOH; whereas there was no statistically significant difference by HIV serostatus in IL-6 (p = 0.84), galectin-3 (p = 0.13), TIMP-2 (p = 0.93), MMP-2 (p = 0.59), or hsTnI (p = 0.31) (Table 2). Only sCD14, GDF-15, and NT-proBNP were evaluated in subsequent analyses.
Table 1  Participant characteristics by HIV serostatus (n = 381)

| Characteristic                                                                 | Median [IQR] or % (n)       | PLWOH (n = 146) | PLWH (n = 235) | p-valuea |
|--------------------------------------------------------------------------------|-----------------------------|-----------------|----------------|----------|
| Parent cohort                                                                  |                             |                 |                | 0.28     |
| MACS                                                                           | 68 (47%)                    | 112 (48%)       |                |          |
| WIHS                                                                           | 22 (15%)                    | 48 (20%)        |                |          |
| ALIVE                                                                          | 56 (38%)                    | 75 (32%)        |                |          |
| **Cardiovascular magnetic resonance imaging metrics**                          |                             |                 |                |          |
| Left atrial volume index, mL/m²                                                | 26.0 (21.4, 32.5)           | 27.7 (22.3, 35.7)| 0.06     |
| Left atrial volume index ≥ 40 mL/m²                                            | 8 (5%)                      | 33 (14%)        | 0.01     |
| **ECV fraction, %**                                                            |                             |                 |                |          |
| ECV fraction ≥ 30% women, ≥ 28% men                                            | 55 (44%)                    | 108 (56%)       | 0.04     |
| LV mass index, g/m²                                                            | 60.9 (55.7, 66.7)           | 61.7 (56.2, 67.8)| 0.51     |
| LV end-diastolic volume index, mL/m²                                            | 64.3 (53.8, 72.7)           | 66.9 (55.8, 76.2)| 0.20     |
| LV end-systolic volume index, mL/m²                                            | 17.5 (13.3, 22.1)           | 18.2 (13.9, 22.7)| 0.16     |
| LV ejection fraction, %                                                        | 73 (68, 76)                 | 72 (68, 76)     | 0.31     |
| **Demographics**                                                               |                             |                 |                |          |
| Age, years                                                                      | 56 (52, 59)                 | 55 (50, 58)     | 0.23     |
| Female                                                                         | 37 (25%)                    | 68 (29%)        | 0.45     |
| Race/ethnicity                                                                  |                             |                 |                | 0.36     |
| Black                                                                          | 95 (65%)                    | 169 (72%)       |          |
| White                                                                          | 40 (27%)                    | 53 (23%)        |          |
| Other                                                                          | 11 (8%)                     | 13 (6%)         |          |
| Education                                                                       |                             |                 |                | 0.03     |
| Less than high school                                                          | 32 (22%)                    | 67 (29%)        |          |
| Completed high school                                                           | 45 (31%)                    | 68 (29%)        |          |
| Some college                                                                   | 19 (13%)                    | 47 (20%)        |          |
| College degree or higher                                                        | 50 (34%)                    | 53 (23%)        |          |
| Annual income > $10,000                                                         | 79 (57%)                    | 139 (62%)       | 0.35     |
| **Substance use**                                                              |                             |                 |                |          |
| Smoking status                                                                  |                             |                 |                | 0.09     |
| Current                                                                        | 59 (40%)                    | 116 (49%)       |          |
| Former                                                                         | 58 (40%)                    | 68 (29%)        |          |
| Never                                                                          | 29 (20%)                    | 51 (22%)        |          |
| Pack-months of smoking among current or former smokersb                         | 11.8 (0.0, 32.9)            | 14.2 (2.0, 36.4)| 0.02     |
| AUDIT hazardous alcohol use                                                     | 21 (14%)                    | 25 (11%)        | 0.28     |
| Marijuana useb                                                                  | 59 (40%)                    | 106 (45%)       | 0.37     |
| Opioid useb                                                                    | 47 (32%)                    | 71 (30%)        | 0.68     |
| Stimulant useb                                                                  | 52 (36%)                    | 95 (40%)        | 0.35     |
| Erectile dysfunction drug useb                                                  | 23 (16%)                    | 41 (17%)        | 0.67     |
| Nitrate useb                                                                   | 22 (15%)                    | 36 (15%)        | 0.95     |
| **Clinical**                                                                   |                             |                 |                |          |
| Body mass index, kg/m²                                                          | 27.1 (24.1, 31.0)           | 26.1 (23.3, 30.8)| 0.08     |
| Hypertension                                                                   | 79 (54%)                    | 123 (52%)       | 0.74     |
| Antihypertensive medication                                                     | 50 (34%)                    | 86 (37%)        | 0.64     |
| Systolic blood pressure, mmHgb                                                  | 128 (121, 135)              | 125 (119, 135)  | 0.10     |
| Diastolic blood pressure, mmHg b                                                | 81 (76, 86)                 | 79 (74, 85)     | 0.10     |
| Dyslipidemia                                                                   | 85 (58%)                    | 143 (61%)       | 0.61     |
| Lipid-lowering medication                                                      | 34 (23%)                    | 58 (25%)        | 0.76     |
| Total cholesterol, mg/dL                                                        | 178 (149, 207)              | 172 (151, 195)  | 0.09     |
| HDL-cholesterol, mg/dL                                                          | 56 (46, 68)                 | 51 (40, 63)     | 0.01     |
Among PLWH, some measures of greater HIV disease severity were associated with higher circulating concentrations of sCD14, GDF-15 and NT-proBNP, independent of demographics and substance use (Additional file 1: Table S1). Associations were observed between CD4+ cell count < 500 cells/µL (yes vs. no) and plasma concentration of sCD14 (mean percent difference in sCD14: 9% higher [95% CI: 2–16], p = 0.01; GDF-15: 15% higher [2–31], p = 0.03; and NT-proBNP: 30% higher [2–65], p = 0.03). Higher NT-proBNP was also associated with detectable HIV viral load (30% higher [1–68]; p = 0.05).

Figure 1 presents adjusted estimates of the association between biomarkers that differed by HIV serostatus in this study population—sCD14, NT-proBNP, and GDF-15—and high LAVI and ECV fraction [11], overall and by HIV serostatus. Among all participants, NT-proBNP was associated with elevated LAVI (odds ratio [OR]: 1.79 per SD increment in NT-proBNP [95% CI: 1.31–2.44]; p < 0.001), following adjustment for age, sex at birth, race/ethnicity, education, pack-years of smoking in 5 years preceding CMR, hazardous alcohol use, dyslipidemia, systolic blood pressure, blood pressure-lowering therapy, diabetes, history of CVD, and HIV infection. No HIV × biomarker interaction term was statistically significant, although subgroup estimates were imprecise due to
rare outcomes and relatively small sample sizes (e.g., only 8 cases with elevated LAVI among those without HIV). Other associations between HIV-associated biomarkers and HIV-associated cardiac structural characteristics were either small or imprecise, both overall and within subgroups defined by HIV serostatus.

Adding NT-proBNP levels to adjusted models estimating the association between HIV and LAVI attenuated the magnitude of the HIV effect estimate slightly but did not alter the statistical significance of the association (OR without adjustment for NT-proBNP: 2.85 [95% CI: 1.26–6.45], \( p = 0.01 \); OR with this adjustment: 2.54 [95% CI: 1.11–5.81], \( p = 0.03 \); 11% decrease).

In sensitivity analyses, parsimonious models excluding non-significant covariates yielded biomarker parameter estimates with consistent magnitude and statistical significance with those in our primary models. Further adjustment for HCV infection and...
recreational drug use also yielded negligible differences in biomarker parameter estimates, as did further adjustment for detectable HIV viral load in subgroup analyses among PLWH.

**Discussion**

Several lines of evidence now suggest PLWH in the current cART era have a higher prevalence of myocardial fibrosis, left atrial dilation, and diastolic abnormalities compared to PLWOH, including among participants within the current study [9–18, 27]. In this population of treated PLWH and PLWOH in the United States, positive HIV serostatus was associated with higher circulating levels of sCD14, GDF-15, and NT-proBNP, consistent with prior literature. When evaluating associations between levels of these three biomarkers and high LAVI or high ECV, there was evidence only of a relationship between NT-proBNP and LAVI, following adjustment for demographics and traditional CVD risk factors. Further, there was no evidence of modification of any effect estimates by HIV serostatus, assessed by HIV × biomarker interaction terms.

Contributors to excess risk of myocardial disease among PLWH are undoubtedly multifactorial, but immune dysfunction and persistent immune activation have been consistently implicated, even in the current cART era [28–34]. The interplay between inflammation, cardiac fibrosis, and cardiac stress is well-appreciated [19, 35], but remains poorly understood in HIV infection, where such relationships may be augmented or differ from those among the general population.

Higher circulating levels of sCD14, GDF-15, and NT-proBNP by HIV serostatus in this study are consistent with previous studies comparing cART-treated PLWH with PLWOH [16, 36–39]. CD14 is a pattern recognition receptor for ligands such as lipopolysaccharide [40]. It is integral to the activation of monocytes and macrophages and is involved in a variety of cellular processes, including host–pathogen interactions and cell differentiation [40]. A higher circulating level of sCD14 is a strong predictor of cardiovascular disease and mortality among both PLWOH and PLWH [41–43]. Consistent with our findings in both men and women, however, sCD14 was not associated with measures of myocardial fibrosis or diastolic dysfunction in a recent study among women living with well-controlled HIV in the United States [16]. The discrepant results in associations of sCD14 observed with clinical events but not subclinical myocardial disease or diastolic dysfunction may be due in part to difference in disease severity and potential differences in the role of monocyte and macrophage activation in atherosclerotic versus hypertensive cardiovascular pathologies [44]. For example, classical CD14 high monocytes are progenitors of M1-type pro-inflammatory and phagocytic macrophages directly involved in atherosclerotic plaque formation, while non-classical CD14 low monocytes are progenitors of M2-type macrophages, which may be pro-fibrotic in the context of chronic hemodynamic stress that can contribute to HF.

GDF-15 is a member of the transforming growth factor β superfamily involved in inflammation and cellular injury [45]. Elevated levels of GDF-15 have been strongly associated with all-cause mortality, incident HF, and poorer HF prognosis among the general population [46–49]. Higher GDF-15 has also been associated with subclinical cardiac structural and functional abnormalities among cART-treated PLWH—including higher LV mass index and lower LV ejection fraction—although conclusions on its association with diastolic dysfunction in particular have been inconsistent between study populations [38, 39]. To our knowledge, the association between GDF-15 and ECV fraction among PLWH has not previously been reported.

NT-proBNP is a powerful clinical biomarker used in diagnosis of HF, secreted in response to myocyte stretch due to increased ventricular preload, and elevated with both systolic and diastolic dysfunction [50]. Among PLWOH, elevated NT-proBNP is highly predictive of not only incident cardiovascular disease and mortality [51] but also subclinical cardiac remodeling, including myocardial fibrosis measured by ECV fraction [52, 53] and both cross-sectional and longitudinal increases in LAVI [54]. Among cART-treated PLWH, higher NT-proBNP has been cross-sectionally associated with higher left ventricular mass index, ECV fraction, and measures of both systolic and diastolic dysfunction [15, 39]. Results of the present study of LAVI are consistent with this literature but are not for ECV fraction, which may reflect lower absolute values and a narrower range of ECV in our study. The mild (11%) attenuation of the association between HIV infection and LAVI with addition of NT-proBNP as a model covariate suggests it may in part reflect HIV-associated differences in LAVI, but other HIV-related factors remain unmeasured and warrant further investigation.

We acknowledge limitations to this study. First, analyses were cross-sectional, so temporality and causation cannot be assessed. Second, sample size was relatively small, limiting our ability to detect small to moderate effect sizes or draw conclusions on effect measure modification by HIV serostatus. This is especially true for analyses of high LAVI, which was rare in our dataset. There are limitations inherent to the evaluated biomarkers, as well, specifically a lack of pathologic specificity. Even NT-proBNP, a well-established clinical biomarker used to
rule out HF diagnosis, cannot reliably discriminate CVD pathologies [55] and may be elevated in extracardiac conditions such as renal insufficiency or systemic inflammation [56]. Interquartile ranges of some evaluated proteins were also relatively narrow, limiting prediction power. Additionally, while the distributions of demographic and key clinical characteristics among the participants in the current study are similar to that of the larger cohort previously published, we cannot rule out the possibility of selection bias due to analytic exclusions. Finally, multiple models were fit in this study, which may have led to type I errors.

In conclusion, our findings support prior literature establishing PLWH in the current cART era continue to have elevated levels of inflammation as well as markers of fibrosis and myocyte stress compared to PLWOH, specifically as measured by sCD14, GDF-15, and NT-proBNP. However, apart from an association between NT-proBNP and LAVI, the evaluated biomarkers do not well explain observed differences in LAVI and myocardial tissue abnormality by HIV serostatus. These results suggest mechanistic pathways other than those captured by the studied biomarkers should be investigated in future studies on excess risk of cardiovascular disease among contemporary cohorts of PLWH.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02835-y.

**Acknowledgements**

We thank all the study participants for their commitment and support of this research.

**Author contributions**

Study conception and/or design: KCW, WSP. Data acquisition: KCW, WSP, MWP, FJP, DAP, JBM, TTB. Data analysis and presentation: CL, SAH, TEP, FB. Manuscript preparation and revision: TEP (major), KCW, WSP, SAH, CL, JBM, TTB, MWP, FJP, DAP, FB. All authors read and approved the final manuscript.

**Funding**

This study was funded by the United States National Institutes of Health (NIH/National Heart, Lung, and Blood Institute [NHLBI]: R01 HL126552 [KCW and WSP] and U01-DA036297 [ALIVE data collection]. Data in this manuscript collected by MACS and WHIS, now the MACS/WHIS Combined Cohort Study [MWCCS], was supported by the NIH: U01-HL146201, U01-HL146193, U01-HL146240, and U01-HL146205 [MACS, WHIS data collection]. Full MWCCS acknowledgement may be found at https://statepi.jhsph.edu/mwccs/acknowledgments/. TEP is supported by NIH/NHLBI Award Number T32 HL007227. TTB is supported in part by K24 AI120834. Architect i2000IR assays for galectin-3, high sensitivity troponin I, and N-terminal prohormone of brain natriuretic peptide were provided by Abbott under a research agreement. This work was also supported in part by a generous grant from Dr. Nancy Grasmick.

**Availability of data and materials**

The datasets analyzed in the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine and was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all subjects.

**Consent for publication**

Not Applicable.

**Competing interests**

TTB has served as a consultant to Janssen, ViV Healthcare, Gilead Sciences, Merck, and Theratechnologies. Other authors declare that they have no competing interests.

**Author details**

1 Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3 Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA. 4 Department of Medicine, Georgetown University Medical Center, Washington, DC, USA. 5 Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 6 Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7 Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 8 Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 9 Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 10 Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Received: 5 July 2022 Accepted: 26 August 2022

Published online: 03 September 2022

**References**

1. Feinstein MJ, Bahiru E, Achenbach C, Longenecker CT, Hsue P, So-Armah K, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214–20.

2. Shah ASV, Stelzl D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100–12.

3. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American heart association. Circulation. 2019;140(2):e98–124.
4. Alonso A, Barnes AE, Guest JL, Shah A, Shao YI, Marconi V. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database. J Am Heart Assoc. 2019;8(14):e012241.

5. Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the veterans aging cohort study. JAMA Cardiol. 2017;2(5):536–46.

6. Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737–43.

7. Tseng ZH, Moffett E, Kim A, Vittinghoff E, Ursell P, Connolly A, et al. Sudden cardiac death and myocardial fibrosis, determined by autopsy, in persons with HIV. N Engl J Med. 2021;384(24):2306–16.

8. Freiberg MS, Duncan MS, Alcorn C, Chang CH, Kundu S, Mumpuni A, et al. HIV infection and the risk of world health organization-defined sudden cardiac death. J Am Heart Assoc. 2021;10(18):e021266.

9. Erqou S, Lodebo BT, Masri A, Altibi AM, Echouffo-Tcheugui JB, Dzudie A, et al. Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis. JACC Heart Fail. 2019;7(2):98–108.

10. deFilippi CR, Grinspoon SK. Myocardial dysfunction with contemporary management of HIV: prevalence, pathophysiology, and opportunities for prevention. JACC Heart Fail. 2019;7(2):109–11.

11. Wu KC, Haddad E, Vanek WM, Patel EA, Pogorzelski DA, Kirk GD, et al. Human immunodeficiency virus infection and deaths in interstitial ventricular fibrosis and left atrial size. Eur Heart J Cardiovasc Imaging. 2021;22:888.

12. Ntusi N, O'Dwyer E, Derrell L, Wainwright A, Pocock S, Clutton-Brock T, et al. HIV-1-related cardiovascular disease is associated with chronic inflammation, frequent pericardial effusions, and probable myocardial edema. Circ Cardiovasc Imaging. 2016;9(3):e004430.

13. Luetkens JA, Doerner J, Schwarze-Zander C, Wasmuth JC, Boesecke C, Niederhauser T, et al. Cytokine levels of soluble CD14 independently predict mortality in HIV-infected patients. J Infect Dis. 2016;213(9):1352–61.

14. Thiara DK, Liu CY, Raman F, Mangat S, Purdy JB, Duarte HA, et al. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis. 2015;212(10):1544–51.

15. Shuldiner SR, Wong LY, Peterson TE, Wolfson J, Jermey S, Saad H, et al. Myocardial fibrosis among antiretroviral therapy-treated persons with human immunodeficiency virus in South Africa. Open Forum Infect Dis. 2021;8(1):ofaa460.

16. Zanni MV, Awadalla M, Toribio M, Robinson J, Stone LA, Cagliero E, et al. Immune correlates of diffuse myocardial fibrosis and diastolic dysfunction among aging women with human immunodeficiency virus. J Infect Dis. 2020;221(18):1315–20.

17. Hsu PT, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail. 2010;3(1):132–9.

18. Doria de Vasconcellos H, Post WS, Ervin AM, Haberen SA, Budoff M, Malvestutto C, et al. Associations between HIV Serostatus and cardiac structure and function evaluated by 2-dimensional echocardiography in the multicenter AIDS cohort study. J Am Heart Assoc. 2021;10(7):e019709.

19. Thomas TP, Grisanti LA. The dynamic interplay between cardiac inflammation and fibrosis. Front Physiol. 2020;11:529075.

20. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS ONE. 2016;11(5):e0155100.

21. Nordell AD, McKenna M, Borges A, Duprez D, Neuhaus J, Neaton JD, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014;3(4):e008844.

22. Hsu PY, Sherzer R, Hunt PW, Schnell A, Bolger AF, Kalapucu S, et al. Cardiotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc. 2012. https://doi.org/10.1161/JAHA.111.000422.

23. Bahrami H, Budoff M, Haberen SA, Rezaeian P, Ketrogletswa K, Tracy R, et al. Inflammatory markers associated with subclinical coronary artery disease: the multicenter AIDS cohort study. J Am Heart Assoc. 2016. https://doi.org/10.1161/JAHA.116.003371.

24. Hanna DB, Lin J, Post WS, Hodis HN, Xue X, Anastos K, et al. Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men. J Infect Dis. 2017;215(9):1352–61.

25. Burdo TH, Lo J, Abbara S, Wei J, Deelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204(8):1227–36.

26. Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, et al. Systemic inflammation, coagulation, and clinical risk in the START trial. Open Forum Infect Dis. 2017;4(4):ofx262.

27. Suthahar N, Meijers WC, Silije HHW, de Zoet RA. From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodeling and perspectives on differential treatment opportunities. Curr Heart Fail Rep. 2017;14(4):235–50.

28. Wada N, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2012;26(4):463–71.

29. Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, Genebat M, Burdo TH, Vanek WM, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204(8):1227–36.

30. Secemsky EA, Sherzer R, Nitta E, Wu AH, Lange DC, Deeks SG, et al. Novel biomarkers of cardiac stress, cardiovascular dysfunction, and outcomes in HIV-infected individuals. JACC Heart Fail. 2015;3(8):S91–9.

31. Kipke J, Margievicis S, Kityo C, Mirembe B, Guggey J, Yen CH, et al. Sex, HIV status, and measures of cardiac stress and fibrosis in Uganda. J Am Heart Assoc. 2021;10(11):e018767.

32. Wu Z, Zhang Z, Lei Z, Lei P. CD41: Biology and role in the pathogenesis of disease. Cytokine Growth Factor Rev. 2019;48:24–31.

33. Sandler NC, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2013;207(8):1215–21.

34. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbidity events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–59.

35. Hunt PW, Sinclair E, Rodriguez B, Chive C, Clagett B, Funderberg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228–38.
44. van der Vorst EPC, Weber C. Novel features of monocytes and macrophages in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 2019;39(2):e30–7.

45. Wischhusen J, Melero I, Fridman WH. Growth/differentiation factor-15 (GDF-15) from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:951.

46. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham heart study. Circulation. 2012;126(13):1596–604.

47. Kempf T, von Haehling S, Peter T, Althoff T, Ciccora M, Doehner W, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(11):1054–60.

48. Anand IS, Kempf T, Rector TS, Tapken H, Althoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation. 2010;122(14):1387–95.

49. Xanthakis V, Larson MG, Wollert KC, Aragam J, Cheng S, Ho J, et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc. 2013;2(6):e000399.

50. Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698–717.

51. Alpert MA. Natriuretic peptides as predictors of cardiovascular events and all-cause mortality. J Am Coll Cardiol. 2021;77(5):572–4.

52. Liu CY, Heckbert SR, Lai S, Ambale-Venkatesh B, Ostovaneh MR, McClelland RL, et al. Association of elevated NT-proBNP with myocardial fibrosis in the multi-ethnic study of atherosclerosis (MESA). J Am Coll Cardiol. 2017;70(25):3102–9.

53. Yang EF, Khan MA, Graviss EA, Nguyen DT, Bhimaraj A, Nambi V, et al. Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. Sci Rep. 2019;9(1):20168.

54. Varadarajan V, Ambale-Venkatesh B, Hong SY, Habibi M, Ashikaga H, Wu CO, et al. Association of longitudinal changes in NT-proBNP with changes in left atrial volume and function: MESA. Am J Hypertens. 2021;34(6):626–35.

55. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

56. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010;51(2):151–63.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.